Skip to main content
Fig. 3 | Neurological Research and Practice

Fig. 3

From: Point-of-care testing for emergency assessment of coagulation in patients treated with direct oral anticoagulants including edoxaban

Fig. 3

Percentage of edoxaban concentrations up to 30 ng/mL (light gray), > 30 and ≤ 50 ng/mL (dark gray) and > 50 ng/mL (black) found at corresponding laboratory-based calibrated anti-Xa activity and the ‘ideal cut-offs’ for Hemochron™ Signature Elite point-of-care test system-based prothrombin time/INR (HC-INR) and activated clotting time (HC-ACT+)

Back to article page

Neurological Research and Practice

ISSN: 2524-3489

Contact us